It is a well known fact that an alteration to a gene sequence, whether it be a mutation, deletion, or substitution, can have varying effects on the final product of that sequence. Sometimes it doesn't affect the sequence at all while other times the results are catastrophic. So it may seem mundane when a research team in the University of Pennsylvania observed such adverse effects when they changed a single gene within a sequence. However, it was what they were aiming to achieve that makes this so interesting.
A led by plant biologist Aman Husbands from the University of Pennsylvania were studying a group of HD-ZIPIII transcription factors, TFs, when they realized that despite using the same materials, these TFs interpreted sequences completely differently. To further study this, they chose two different TFs, CORONA, CNA, and PHABULOSA, PHB. They found that these two TFs would bind to the same region on the DNA but noticed a difference in their START domains, the lipid-binding region of the TFs. Concluding that these START domains dictated how these TFs interpreted the sequence, they decided to switch the START domains of CNA and PHB. By mapping out the results, the researchers found that the START regions regulated what genes the TF could bind to, ultimately changing the final product. Aman Husbands, parodying a Latin phrase, called this "Out of one, many" referring to how a single change in the START domain creates a brand new template for binding sites, one change, many possibilities.
As with most discoveries, the possible medical use for this is immense. While this type of experimentation is new, the researchers are trying to see what different kinds of changes to the START domain will cause. It would be interesting if this could be used to fix genetic disorders caused by mutations or if it could be used to suppress harmful disorders.